BioSpace News Archive

Leading provider of premium medical devices and hygiene products successfully launchesSuprasorb® CNP P3 and Debrisoft Pad for the first time in the region

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.

Have you ever experienced a career epiphany but lacked the resolve to act on it? Don’t feel bad, especially if “acting on it” meant leaving a secure, albeit unfulfilling, job for a new career in a different industry.

Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company’s existing shareholders.

MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.

On January 3, Bristol-Myers Squibb announced it was buying Celgene for $74 billion. This would create a giant company with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease. As the companies release their fourth-quarter results, more details about the combined companies’ plans are emerging.

Biom’up today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United States, effective today.

The first treatment in this final study prior to the application for marketing authorization for the gp-ASIT+™ product candidate on the German market was undertaken on schedule at the Memmingen medical center in Germany

Repare Therapeutics, Inc. announced that it has entered into an exclusive strategic research, development and commercialization partnership with ONO Pharmaceutical Co., Ltd., for Repare’s small molecule Polθ inhibitor program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China.